52 completed, 12 unknown, 7 terminated, 4 withdrawn. 23 Phase 2, 21 Not applicable, 20 Phase 3, 6 Phase 4, 3 Early Phase 1.
Follow Raynaud Disease: new trials by email Literature Review of Raynaud Disease trials Research Report on Raynaud Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | Liquidia Technologies, Inc. | 75 | 2026-10-26 | 2026-08-07 |
| Open Label Treprostinil Raynaud's Study Oral treprostinil (UT-15C) sustained release tablets - Raynaud's Disease, Raynaud Phenomena | Phase 4 | Recruiting | Brigham and Women's Hospital | 30 | 2025-10-15 | 2026-03-24 |
| The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life Apollo Neuro Device, Sham device - Systemic Sclerosis (SSc) | Not applicable | Recruiting | Robyn T. Domsic, MD, MPH | 160 | 2025-01-06 | 2026-01-08 |
| Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot Observation - Nailfold capillaroscopy - Systemic Sclerosis, Raynaud Phenomenon | Completed | University of Manchester | 112 | 2023-11-22 | 2025-04-03 | |
| Multi-modal Quantitative Imaging of the Skin Skin Cancer, Skin Diseases | Recruiting | HJN Sverige AB/Neko Health | 8000 | 2023-02-01 | 2025-05-25 | |
| Treatment of Frostbite Sequelae With Botulinum Toxin A Botuinum toxin - Cold Hypersensitivity, Vascular System Injuries | Phase 2 | Withdrawn | University Hospital of North Norway | 2022-11-01 | 2024-06-14 | |
| Phototherapy For Treatment Of Raynaud's Phenomenon Blue Light Therapy, Sham Light Therapy - Raynaud Disease, Raynaud Phenomenon | Not applicable | Withdrawn | University of Minnesota | 2022-08-01 | 2023-01-06 | |
| Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis Rheopheresis treatment, Intravenous Infusion - Systemic Sclerosis, Raynaud Phenomenon | Not applicable | Unknown | Peter Korsten | 30 | 2022-02-28 | 2022-03-23 |
| Botulinum Toxin in Raynaud's Phenomenon Botulinum toxin - Raynaud Phenomenon | Phase 4 | Completed | Emory University | 24 | 2022-02-10 | 2026-07-29 |
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis Temanogrel, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Terminated | Pfizer | 13 | 2021-11-03 | 2023-12-22 |
| Functional Exercise Tests in Patients With Systemic Sclerosis 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test - Scleroderma, Systemic, Lung Diseases, Interstitial | Unknown | University of Aarhus | 83 | 2021-07-27 | 2022-05-20 | |
| Dermoscopy in Primary Raynaud's Phenomenon Dermoscopy - Raynaud Phenomenon | Completed | Assistance Publique - Hôpitaux de Paris | 100 | 2021-01-01 | 2021-07-20 | |
| Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon L-citrulline, Beetroot juice, L-citrulline placebo - Raynaud Phenomenon | Not applicable | Unknown | University Hospital, Grenoble | 30 | 2020-10-01 | 2021-05-14 |
| Apollo Device for Fatigue in Systemic Sclerosis Apollo - Systemic Sclerosis, Fatigue | Not applicable | Completed | Robyn T. Domsic, MD, MPH | 25 | 2020-07-07 | 2025-04-02 |
| Application for Monitoring and Evaluation of Raynaud's Phenomenon Smartphone application - Raynaud Phenomenon | Unknown | University Hospital, Grenoble | 120 | 2020-03-31 | 2023-12-06 | |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
| Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease hyaluronidase injected intradermally - Microstomia, Scleroderma | Early Phase 1 | Withdrawn | Brigham and Women's Hospital | 2020-01-01 | 2021-01-14 | |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Civi Biopharma, Inc. | 198 | 2019-10-14 | 2025-05-25 |
Showing 20 of 81. Sign in to see all of them.
Scleroderma, Systemic (28) · Scleroderma, Diffuse (23) · digital ulcers (4) · CREST Syndrome (3) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Fatigue (2) · Pain (2) · Peripheral Vascular Diseases (2) · Vascular Diseases (2) · Acro-Osteolysis (1) · Arthritis (1) · Calcinosis Cutis (1) · Calciphylaxis (1)
Embolism and Thrombosis (81) · Livedoid Vasculopathy (81) · Skin Diseases, Vascular (81) · Skin and Connective Tissue Diseases (81) · Thrombosis (81) · Cardiovascular Diseases (80) · Skin Diseases (80) · Peripheral Vascular Diseases (79) · Vascular Diseases (79) · Connective Tissue Diseases (42) · Scleroderma, Systemic (16) · Pathological Conditions, Signs and Symptoms (10) · Immune System Diseases (6) · Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5)
Nitroglycerin (8) · Botulinum Toxins, Type A (4) · Tadalafil (4) · Botulinum Toxins (3) · Iloprost (3) · treprostinil (3) · Alprostadil (2) · Biofeedback, Psychology (2) · Cilostazol (2) · Saline Solution (2) · Sildenafil Citrate (2) · Sodium Chloride (2) · Sugars (2) · abobotulinumtoxinA (2) · APD791 (1)
MediQuest Therapeutics (8) · University Hospital, Grenoble (6) · Brigham and Women's Hospital (3) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (3) · Assistance Publique - Hôpitaux de Paris (2) · Civi Biopharma, Inc. (2) · Emory University (2) · Johns Hopkins University (2) · Otsuka America Pharmaceutical (2) · Pfizer (2) · Robyn T. Domsic, MD, MPH (2) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (2) · Seoul National University Hospital (2) · Actelion (1) · Artgen Biotech (1)
United States (33) · France (12) · United Kingdom (9) · Germany (8) · Canada (6) · South Korea (3) · Sweden (3) · Denmark (2) · Netherlands (2) · Spain (2) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1) · Hungary (1)
Robyn T Domsic, MD (2) · Wade Benton, Pharm D (2) · Aaron B Waxman, MD, PhD (1) · Aaron Waxman, MD/PhD (1) · Aman Sharma, MD (1) · Amanda Lynggaard Riis, Student (1) · Andreea Valdman, MD (1) · Anne Laumann, MBChB, MRCP (1) · Ariane E Herrick, MD, FRCP (1) · Ariane Herrick, MD (1) · Ariane L Herrick, MB,ChB, MD (1) · Arne J Norheim, PhD (1) · Barbara Troupin, MD, MBA (1) · Bashar Kahaleh, MD (1)
PMID 37929840, PMID 19194764, PMID 19734516, PMID 20627413, PMID 20837499, PMID 21476099, PMID 21868066, PMID 22370242, PMID 23370086, PMID 24352340, PMID 24489014, PMID 24990822, PMID 26808752, PMID 28426903, PMID 28452678, PMID 28509693, PMID 29037377, PMID 29193819, PMID 29871697, PMID 30383134, PMID 30463598, PMID 31220505, PMID 31933034, PMID 33804657, PMID 33998674, PMID 35358372, PMID 35492333, PMID 35894657, PMID 36066501, PMID 38340159, PMID 39617410, PMID 42643722
2005 (1), 2014 (1), 2019 (1)